Physicians' Academy for Cardiovascular Education

New therapeutic options can make a difference for diabetic patients with high CV risk

Aug. 29, 2017 - Prof. John E Deanfield, MD - London, UK

Novel insights in the management and prognosis of pulmonary hypertension

Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Cardiovascular protection in type 2 diabetes

Aug. 29, 2017 - Prof. Lars Rydén, cardiologist, Stockholm, Sweden

BP lowering with endovascular baroreflex amplification in resistant hypertension: the CALM-FIM study

Aug. 29, 2017 - Dr. Wilko Spiering - UMCU

Take home messages of the ESC congress for better hypertension treatment

Aug. 29, 2017 - Dr. Clyde Jancy - Northwestern University, Feinberg University, Chicago, IL, VS

Una nueva era para la prevención cardiovascular: anti-inflamatorios además de la reducción lípidica.

Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Lina Badimon

A new era of CV prevention: Anti-inflammatory drugs on top of lipid lowering

Aug. 29, 2017 - ESC 2017, Barcelona, Spain

MRA treatment early after STEMI may give mortality benefit

Aug. 30, 2017

A new challenge for precision medicine: selecting major contributing risk factors

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Dopo 23 anni, lo studio CANTOS confermi l'ipotesi sull'infiammazione

Aug. 29, 2017 - ESC 2017, Barcelona, Spain

Diverse study data confirm the rationale of intensive lipid-lowering

Aug. 29, 2017 - Christie Ballantyne - Houston, Texas, VS

Imaging components of plaque not more informative than burden of plaque

Aug. 30, 2017 - Stephen Nicholls, MD, Adelaide, Australia

L’inflammation est critique dans la prévention secondaire des évènements cardiovasculaires

Aug. 28, 2017 - ESC 2017, Barcelona, Spain

The journey from vascular biology to the clinic: reducing inflammation lowers CV risk

Aug. 28, 2017

Well-conducted trial confirms principle that renal denervation can lower blood pressure

Aug. 29, 2017

First time CV reduction is achieved with CETP inhibition

Aug. 29, 2017

Large population study underscores that 'all in moderation' is still good nutrition advice

Aug. 29, 2017

Achieving very low LDL-c levels (<0.5 mmol/L or <20 mg/dL) with PCSK9 inhibition is safe and effective

Aug. 28, 2017

Natural randomisation shows that mode of LDL-lowering determines CV benefit

Aug. 28, 2017

LDL-c still reduced after 1 year with siRNA against PCSK9

Aug. 28, 2017

NSAID ibuprofen increases blood pressure significantly more than other selective COX2 inhibitors

Aug. 28, 2017

Decades of science on the inflammatory hypothesis of atherosclerosis translate into actionable clinical therapeutic to reduce residual CV risk

Aug. 27, 2017

NOAC plus aspirin combination therapy better than aspirin alone to reduce CV events in CAD and PAD

Aug. 27, 2017

Lowering inflammation without affecting LDL-c benefits aggressively treated CV patients

Aug. 27, 2017

New therapeutic options can make a difference for diabetic patients with high CV risk

Aug. 29, 2017 - Prof. John E Deanfield, MD - London, UK
Prof. John Deanfield states that the introduction of two new drug classes with CV benefits can really make a difference for the CV outcomes of high-risk diabetic patients

Prof. John Deanfield states that the introduction of two new drug classes with CV benefits can really make a difference for the CV outcomes of high-risk diabetic patients

Novel insights in the management and prognosis of pulmonary hypertension

Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy
Prof. Galiè summarizes new results regarding pulmonary hypertension (PH) that were presented at ESC 2017, separately for each clinical PH group. Treatment options expand and some can improve patient outcomes.

ESC 2017 Prof. Galiè summarizes new results regarding pulmonary hypertension (PH) that were presented at ESC 2017, separately for each clinical PH group. Treatment options expand and some can improve patient outcomes.

Cardiovascular protection in type 2 diabetes

Aug. 29, 2017 - Prof. Lars Rydén, cardiologist, Stockholm, Sweden
Prof. Lars Rydén describes two classes of drugs that may protect patients with type 2 diabetes from CV events. Depending on the type of patient, cardiologists can choose  a drug.

Prof. Lars Rydén describes two classes of drugs that may protect patients with type 2 diabetes from CV events. Depending on the type of patient, cardiologists can choose a drug.

BP lowering with endovascular baroreflex amplification in resistant hypertension: the CALM-FIM study

Aug. 29, 2017 - Dr. Wilko Spiering - UMCU
Dr. Wilko Spiering summarises the results of the CALM-FIM study, showing that endovascular baroreflex amplification with MobiusHD device lowers BP in resistant hypertension.

ESC 2017 Dr. Wilko Spiering summarises the results of the CALM-FIM study, showing that endovascular baroreflex amplification with MobiusHD device lowers BP in resistant hypertension.

Take home messages of the ESC congress for better hypertension treatment

Aug. 29, 2017 - Dr. Clyde Jancy - Northwestern University, Feinberg University, Chicago, IL, VS
Clyde Yancy summarises insights of studies presented at the ESC on managment of hypertension and associated CV risk, which can help understanding of how treatment can be improved.

ESC 2017 Clyde Yancy summarises insights of studies presented at the ESC on managment of hypertension and associated CV risk, which can help understanding of how treatment can be improved.

A new era of CV prevention: Anti-inflammatory drugs on top of lipid lowering

Inflammation expert opinions

Aug. 29, 2017 - ESC 2017, Barcelona, Spain
Lina Badimon explains why blocking inflammation may have significant clinical benefit, as inflammation is important in plaque formation.

Inflammation Expert Opinions Lina Badimon explains why blocking inflammation may have significant clinical benefit, as inflammation is important in plaque formation. The results of CANTOS can be the dawn of a new era of CV prevention.

MRA treatment early after STEMI may give mortality benefit

ESC 2017 - Barcelona

Aug. 30, 2017
A patient-level pooled analysis of REMINDER and ALBATROSS data suggests that there may be a mortality benefit of treating STEMI patients with a mineralocorticoid receptor antagonist.

ESC 2017 A patient-level pooled analysis of REMINDER and ALBATROSS data suggests that there may be a mortality benefit of treating STEMI patients with a mineralocorticoid receptor antagonist.

A new challenge for precision medicine: selecting major contributing risk factors

Inflammation expert opinions

Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Erik Stroes summarizes the results from CANTOS and states that for daily clinical practice, it is important to select the major factors contributing to CV risk

Inflammation Expert Opinions Erik Stroes summarizes the results from CANTOS and states that for daily clinical practice, it is important to select the major factors contributing to CV risk

Dopo 23 anni, lo studio CANTOS confermi l'ipotesi sull'infiammazione

Aug. 29, 2017 - ESC 2017, Barcelona, Spain
Filippo Crea riflette su una pubblicazione del 1994, introducendo l’ ipotesi sull’infiammazione e spiega come lo studio CANTOS confermi tale ipotesi.

Inflammation Expert Opinions Filippo Crea riflette su una pubblicazione del 1994, introducendo l’ ipotesi sull’infiammazione e spiega come lo studio CANTOS confermi tale ipotesi. La sfida ora è individuare i pazienti che trarranno beneficio da questo trattamento.

Diverse study data confirm the rationale of intensive lipid-lowering

ESC 2017 - Barcelona

Aug. 29, 2017 - Christie Ballantyne - Houston, Texas, VS

ESC 2017 Dr. Christie Ballantyne summarises results of diverse studies into various lipid lowering therapies, both approved and experimental strategies, and concludes that they all reinforce current guidelines.

Imaging components of plaque not more informative than burden of plaque

ESC 2017 Barcelona

Aug. 30, 2017 - Stephen Nicholls, MD, Adelaide, Australia
Virtual histology of components of plaque does not provide additional information in the serial imaging GLAGOV study that showed more coronary atherosclerosis regression when PCSK9 inhibitor evolocumab was added to intensive statin-treatment.

ESC 2017 Virtual histology of components of plaque does not provide additional information in the serial imaging GLAGOV study that showed more coronary atherosclerosis regression when evolocumab was added to intensive statin-treatment.

The journey from vascular biology to the clinic: reducing inflammation lowers CV risk

Inflammation expert opinions

Aug. 28, 2017
Paul Ridker and Peter Libby look back at the evolution of their research efforts on the role of inflammation in CV risk, and how they saw their hypothesis confirmed in the CANTOS trial.

Inflammation Expert Opinions Paul Ridker and Peter Libby look back at the evolution of their research efforts on the role of inflammation in CV risk, and how they saw their hypothesis confirmed in the CANTOS trial.